EpCAM
1 EU-approved indication of 1 drug needs a EpCAM result, in 1 tumour type, most of them in solid tumours, tumour-agnostic.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Solid tumours, tumour-agnostic1 | ||||
Korjuny | Monotherapy | 2L | Malignant ascites; not eligible for further systemic anticancer therapy | |
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Catumaxomab (Korjuny)
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.